All IndicationsOncologyPhase 2Phase 2Phase 2Phase 2Phase 2Phase 2
🎗️
Carcinoma, Non-Small-Cell Lung
6
Companies
6
Drug Programs
0
Phase 3
0
Upcoming PDUFAs
Competitors
SGEN
Seagen Inc.
SGN-15
CASI
CASI Pharmaceuticals, Inc.
recombinant human Angiostatin protein
PBYI
PUMA BIOTECHNOLOGY, INC.
HKI-272
JNJ
Johnson & Johnson
JNJ-90301900
LLY
Eli Lilly and Company
IMC-1121B (ramucirumab)
GTHX
G1 Therapeutics, Inc.
G1T38
| Company | Drug | Phase | Designations | Timeline | Trial ID |
|---|---|---|---|---|---|
| SGEN Seagen Inc. | SGN-15 | Phase 2 | — | — | — |
| CASI CASI Pharmaceuticals, Inc. | recombinant human Angiostatin protein | Phase 2 | — | — | — |
| PBYI PUMA BIOTECHNOLOGY, INC. | HKI-272 | Phase 2 | — | — | — |
| JNJ Johnson & Johnson | JNJ-90301900 | Phase 2 | — | — | — |
| LLY Eli Lilly and Company | IMC-1121B (ramucirumab) | Phase 2 | — | — | — |
| GTHX G1 Therapeutics, Inc. | G1T38 | Phase 2 | — | — | — |
Development Stage Distribution
Phase 2
6
PDUFA Timeline
No upcoming PDUFA dates for this indication.
Not Financial Advice
All predictions are probabilistic and based on historical data. Past performance does not guarantee future results. Consult a qualified financial advisor.